Effects of long-term coadministration in the general population are unknown. Make adjustments if necessary see System Suitability under Chromatography Increased creatinine, gout, hyperlipemia, hyperuricemia. Information on acute overdosage with cilostazol in humans is limited. Effects on circulating plasma lipids have been examined in patients taking cilostazol.
A Cilostazol dosage of mg twice daily consistently inhibited platelet aggregation induced with arachidonic acid, collagen and adenosine diphosphate ADP.
The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparationas obtained in the Assay. Multiple doses of clopidogrel do not significantly increase steady state plasma concentration of cilostazol. Since cilostazol is extensively metabolized by cytochrome P isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP34 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
This information does not take the place of talking to your doctor about your medical condition or your treatment. The recommended dosage of Cilostazol is mg twice daily taken at least half an hour before or two hours after breakfast and dinner.
The pharmacokinetics of Cilostazol and its metabolites were similar in subjects with mild hepatic disease as compared to healthy subjects. Improvements in walking performance were seen in the various subpopulations evaluated, including those defined by gender, smoking status, diabetes mellitus, duration of peripheral artery disease, age, and concomitant use of beta blockers or of calcium channel blockers.
The most frequent doses and mean durations of aspirin therapy were 75 to 81 mg daily for days patients and mg daily for 54 days 85 patients. Agranulocytosis is reversible on discontinuation of Cilostazol.
Your doctor may recommend a surgical procedure to bypass the blocked segment of the artery. Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.
A randomized, double-blind, placebo-controlled Phase IV study was conducted to assess the long-term effects of cilostazol, with respect to mortality and safety, in patients with intermittent claudication and no heart failure. At this dose, systemic exposures AUCs to unbound Cilostazol were less than 1.
In humans, heart rate increased in a dose-proportional manner by a mean of 5.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Cilostazol related compound B 2. Cilostazol is eliminated predominantly by metabolism and subsequent urinary excretion of metabolites.
Caution is advised in patients receiving both cilostazol and any other antiplatelet agent, or in patients with thrombocytopenia.
Mechanism of Action
You can ask your pharmacist for a list of medicines that interact with Cilostazol. Cilostazol is a prescription medicine used to reduce the symptoms of intermittent claudication and can increase your ability to walk further distances.
The trial stopped early due to enrollment difficulties and a lower than expected overall death rate. The maximum doses administered in both rat and mouse studies were, on a systemic exposure basis, less than the human exposure at the MRHD of the drug. You should discuss possible side effects with your doctor before taking Cilostazol Tablets USP and any time you think you are having a side effect.